Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059949 | 1.00 | GABRA5 (0.41) | GABRA5SLC6A1GABRB2SLC6A12SLC6A11 | |
| SCHEMBL321293 | 1.00 | GABRA5 (0.41) | GABRA5SLC6A1GABRB2SLC6A12SLC6A11 | |
| SCHEMBL1359554 | 0.89 | SCN9A (0.40) | KDM1ABRD4ATAD2CYP3A4JAK2 | |
| SCHEMBL1359859 | 0.89 | SCN9A (0.40) | KDM1ABRD4ATAD2CYP3A4JAK2 | |
| SCHEMBL1358284 | 0.89 | SCN9A (0.40) | KDM1ABRD4ATAD2CYP3A4JAK2 | |
| SCHEMBL122137 | 0.88 | ALOX15 (0.42) | GABRA5GABRA1KDM1AMAOBLMNA | |
| Hydrochloric Acid SCHEMBL26599945 | 0.86 | GNAI3 (0.43) | GABRA5GABRA1KDM1AMAOBLMNA | |
| SCHEMBL21358565 | 0.84 | JAK2 (0.32) | KDM1AMAOBJAK2JAK1TYK2 | |
| Hydrochloric Acid SCHEMBL1702766 | 0.82 | JAK2 (0.31) | JAK2JAK1TYK2JAK3ADRA2A | |
| SCHEMBL21193104 | 0.78 | SSTR4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590960-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-11 | — | — | EP | claimed |
| US-20130209397-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2013-08-15 | — | — | US | claimed |
| US-8329712-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | claimed |
| US-20120009144-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2012-01-12 | — | — | US | claimed |
| US-20250059190-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-12084438-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2024-09-10 | — | — | US | disclosed |
| CN-117659010-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-111867581-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| EP-3746071-A1 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-12-09 | — | — | EP | disclosed |
| CN-111867581-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2012004212-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8063072-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| WO-2011033045-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| US-20110070189-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | LI JIM | 2011-03-24 | — | — | US | disclosed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070189-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RTF2 | GABRA5 4097/4885SLC6A1 4606/4885GABRB2 3933/4885 |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | GABRA5 4584/4885SLC6A1 4671/4885GABRB2 4122/4885 |
| US-12084438-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | GABRA5 4415/4885SLC6A1 3044/4885GABRB2 3461/4885 |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, IRF3 | GABRA5 4687/4885SLC6A1 4698/4885GABRB2 3853/4885 |
| US-20130209397-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, MAVS | GABRA5 4325/4885SLC6A1 4524/4885GABRB2 3988/4885 |
| US-20250059190-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | GABRA5 4415/4885SLC6A1 3044/4885GABRB2 3461/4885 |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | GABRA5 4415/4885SLC6A1 3044/4885GABRB2 3461/4885 |
| US-20120009144-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RNASE1 | GABRA5 4451/4885SLC6A1 4444/4885GABRB2 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.